ROLE OF VITAMIN D3 IN THE MANAGEMENT OF SICKLE CELL DISEASE (SCD)

ROLE OF VITAMIN D3 IN THE MANAGEMENT OF SICKLE CELL DISEASE (SCD): A RANDOMIZED-CONTROLLED TRIAL OF PATIENTS IN LAGOS STATE, NIGERIA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202202814392581

Enrollment

300

Registered

2022-02-03

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders

Interventions

Vitamin D3

Routine Medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age: Patients between 1 year and 12 years Gives informed consent to participate Sickle cell disease, confirmed by laboratory tests

Exclusion criteria

Exclusion criteria: Age: 12years Consume more than 1000 IU per day of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium plus vitamin D supplements, medications with vitamin D, and multivitamins) in the past 4 weeks. Unable to complete questionnaires or adhere to study requirements Presence of complications like leg ulcers, strokes, and avascular necrosis of the head of the femur

Design outcomes

Primary

Measure	Time frame
Rate of crises (per month) and average crises rate through the study Average Packed Cell Volume in two months	—

Secondary

Measure	Time frame
Rate of healthcare visits (including hospitalizations related to infections) per month Average pain level (using pain scale) in two months	—

Countries

Nigeria

Contacts

Public ContactJames Umeadi

Operations Manager

james@brainandbodyfoundation.org+2348034377303

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026